Indication change for Naprosyn EC

Naprosyn EC (enteric-coated/gastro-resistant naproxen) is no longer indicated for the treatment of acute gout or juvenile rheumatoid arthritis following a change to the product's licence.

Naprosyn uncoated tablet formulations may still be used for these indications. For acute gout, the recommended dose is 750 mg once, then 250 mg eight hourly until the attack has passed. For juvenile rheumatoid arthritis in children aged 5 years of age and over the recommended dose is 10mg/kg/day taken in two divided doses at 12 hour intervals.

Naprosyn should not be used for any indications other than juvenile rheumatoid arthritis in children under 16 years of age.

Further information: Roche Products Ltd, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire AL7 1TW. Tel: (01707) 366000.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases